<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606618</url>
  </required_header>
  <id_info>
    <org_study_id>B110797-30</org_study_id>
    <nct_id>NCT01606618</nct_id>
  </id_info>
  <brief_title>Self-esteem and Neuro-urological Follow-up in Patients With Spina Bifida or Spinal Cord Injury</brief_title>
  <acronym>ESTIME</acronym>
  <official_title>Analysis of Psychosocial Determinants of Observance of Monitoring Neuro-urological in Spina-bifida Adult Patients and in Spinal Cord Injury Patients: a Prospective, Comparative, Multicenter With Parallel Groups Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With improved life expectancy over the last fifty years, spina bifida has become a disease of
      the adult. One of the major stakes for these patients is the preservation of a regular
      follow-up of uro-nephrologicals risk factors and of a respect for the rules of self
      management of their neurological bladder.

      The main objective of this study is to highlight a difference in the level of global
      self-esteem among a population of adult patients with spina bifida and a population of adult
      patients with traumatic spinal cord injury gained the same level of neurological.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With improved life expectancy over the last fifty years, spina bifida has become a disease of
      the adult. The risk of developing a terminal renal insufficiency is eight times higher than
      the risk in the general population and twice as important as in acquired spinal cord injury.
      This risk continues to evolve with advancing age.

      One of the major stakes for these patients is the preservation of a regular follow-up of
      uro-nephrologicals risk factors and of a respect for the rules of self management of their
      neurological bladder. However, some studies report that nearly two thirds of these patients
      are not monitored at regular neuro-urological in the adulthood. Different psychosocial
      determinants were analyzed as potential markers of the impact of chronic diseases from
      childhood to adulthood and could account for the disparity of follow-up and access to
      healthcare. Among these, the self-esteem is a psychological dimension of analysis
      particularly relevant within the framework of chronic states inherited from the childhood.

      The investigators formulate the hypothesis that global self-esteem and lower perceived
      self-efficacy may be a causal predictive factor of a reduced access to the continence and a
      lower compliance monitoring in adult patients with a spina bifida.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the global self-esteem by the Rosenberg scale (RSES)</measure>
    <time_frame>At day 0</time_frame>
    <description>Score range : 10 - 40. High scores indicate hight self esteem.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of depression and anxiety by Hamilton's scale (HAD)</measure>
    <time_frame>At day 0, at month 6</time_frame>
    <description>Score range : 0 - 21. High scores indicate a hight level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological evaluation (WAIS-III battery composite GREFEX, CVLT)</measure>
    <time_frame>At day 0</time_frame>
    <description>Battery of test exploring executives functions. High scores indicate high level of executive functions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating Scale vesico-sphincter and anorectal function (ISCOS)</measure>
    <time_frame>At day 0, at month 6</time_frame>
    <description>High scores indicate high vesico-sphincter and anorectal dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation scale for the achievement of self catheterizing</measure>
    <time_frame>At day 0, at month 6</time_frame>
    <description>14 binary items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale functional mobility and transfers (SCIM III)</measure>
    <time_frame>At day 0</time_frame>
    <description>The SCIM is a disability scale in order to describe patients' ability to accomplish activities of daily living and to make functional assessments of this population more sensitive to changes.
SCIM-III is comprised of 19 items in 3 subscales, which are:
(i) self-care (sub-score 0-20); (ii) respiration and sphincter management (sub-score 0-40); (iii) mobility (sub-score 0-40). The mobility subscale is further sub-divided to assess mobility &quot;in room and toilet&quot; and for &quot;indoors and outdoors, on an even surface&quot;.
The total score ranges from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the global self-esteem by the Rosenberg scale (RSES)</measure>
    <time_frame>At month 6</time_frame>
    <description>Score range : 10 - 40. High scores indicate hight self esteem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of the appointment</measure>
    <time_frame>At month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of holding of the mictionnel catalog</measure>
    <time_frame>At month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of auto-efficiency experienced scale for Medullary Injured (MSES)</measure>
    <time_frame>At Day 0</time_frame>
    <description>16 items ranging from 1 to 7
Range 16 - 112
High scores correspond to low level of percieved auto-efficiency</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Spina Bifida Aperta</condition>
  <condition>Acquired Traumatic Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Spina bifida aperta</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Acquired traumatic spinal cord injury</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient seen in university hospitals or in rehabilitation clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a spina bifida aperta or an acquired traumatic spinal cord injury dating
             more than two years, the level of injury being below D12 and higher S1 (Score ASIA A).

          -  Age between 18 and 60

          -  Knowing how to read, write, count

          -  Having given their free, informed and in writing consent (an information is also given
             to the reliable person when it exists)

          -  Affiliated to the National Health Service

        Exclusion Criteria:

          -  Psychiatric history requiring an hospitalization in a specialized unit during more
             than two months

          -  Score MMS lower than 27 ( GRECO version)

          -  Serious associated pathology or associated pathology which could interfer with the
             management of vesico-sphincteral disorders

          -  Neurosurgery, dating from less than one year

          -  Symptoms of dysfunction of ventricular bypass valve at the time of inclusion

          -  Clinical epileptic attack within six months prior to inclusion

          -  Pregnancy or breastfeeding

          -  Simultaneous inclusion in an another therapeutic protocol or period of exclusion from
             an another protocol

          -  Traumatic spinal cord injury acquired before age 16
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Kerdraon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reymann Jean Michel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Kerdraon, MD</last_name>
    <phone>2 99 28 97 63</phone>
    <phone_ext>+33</phone_ext>
    <email>Jacques.KERDRAON@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Parratte</last_name>
    </contact>
    <investigator>
      <last_name>Bernard Parratte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne de Sèze, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marianne de Sèze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Blanchard Dauphin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Blanchard Dauphin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologie CH Lyon Sud et Hôpital Henry Gabrielle</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Ruffion, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain Ruffion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Conception Service de chirurgie urologique et transplantation rénale</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Karsenty, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles Karsenty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MPR neurologique CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Perrouin Verbe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte Perrouin Verbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Raymond Poincaré</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Denys, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Denys, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberte Robain, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilberte Robain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-urologie et explorations périnéales, APHP Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Amarenco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerard Amarenco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE</name>
      <address>
        <city>Ploemeur</city>
        <zip>56270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Kerdraon, MD</last_name>
      <phone>2 97 82 60 60</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Loïc Lemoigne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes CR Spina bifida</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Kerdraon</last_name>
      <email>Jacques.KERDRAON@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Kerdraon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Manunta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Berkelmans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou - CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Bonan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Bonan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MPR St Hélier</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Gallien</last_name>
      <email>philippe.gallien@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Gallien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologie, CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Grise, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Grise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MPR CHU Rangueuil</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyne Castel Lacanal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evelyne Castel Lacanal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologie CHU Rangueuil Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Game, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Game, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Self-esteem</keyword>
  <keyword>Spina Bifida</keyword>
  <keyword>Spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Spinal Dysraphism</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

